Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

COVID-19 6Neoplasms 2Hematologic Neoplasms 2Severe Acute Respiratory Syndrome 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Mastocytosis 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hypersensitivity 1Hematopoietic and Lymphatic System Neoplasm 1Chronic Disease 1

Interventions

masitinib 4Imatinib Mesylate 3midostaurin 1fludarabine phosphate 1fludarabine 1avapritinib 1Whole-Body Irradiation 1Watchful Waiting 1Transplantation 1Tacrolimus 1Stem Cell Transplantation 1Sodium Chloride 1Single-Cell Gene Expression Analysis 1Radiotherapy 1Phlebotomy 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Mass Screening 1Injections 1Hydroxychloroquine 1Dasatinib 1Cyclophosphamide 1Cromolyn Sodium 1Cladribine 1Busulfan 1BNT162 Vaccine 1AK002 12019-nCoV Vaccine mRNA-1273 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mastocytosis × BNT162 Vaccine × Clear all
NCT04761822 2025-08-12

SARS

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
746 enrolled 28 charts
Myeloid

COVID-19, Hypersensitivity, Mastocytosis, Severe Acute Respiratory Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡